Michael von Bergwelt-Baildon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael von Bergwelt-Baildon has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Shimabukuro-Vornhagen
Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
13 shared publications - Matthias Kochanek
Klinik I für Innere Medizin, Universitätsklinikum Köln, Köln, Deutschland
9 shared publications - Guido Michels
Klinik III für Innere Medizin, Herzzentrum, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
5 shared publications M. Hallek
Universitätsklinikum Köln und Centrum für Integrierte Onkologie Köln-Bonn
3 shared publications- Michael Hallek
Universität zu Köln
3 shared publications - Achim Rothe
OTC (Oncological Therapy Center), Cologne, Germany
2 shared publications
Latest Publications
- 27 September 2017
- Published by Springer Nature in Intensive Care Medicine
- Vol. 44 (3) , 371-373
Understanding cytokine release syndrome
- 27 September 2017
- Published by Springer Nature in Intensive Care Medicine
- Vol. 44 (3) , 371-373
Understanding cytokine release syndrome
- Open Access
- 16 May 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (27) , 44418-44433
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
- 16 May 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (27) , 44418-44433
Open AccessCharacterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
- 27 June 2016
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 66 (6) , 496-517
Critical care of patients with cancer
Answer questions and earn CME/CNE The increasing prevalence of patients living with cancer in conjunction with the rapid progress in cancer therapy will lead to a growing number of patients with cancer who will require intensive care treatment. Fortunately, the development of more effective oncologic therapies, advances in critical care, and improvements in patient selection have led to an increased survival of critically ill patients with cancer. As a consequence, critical care has become an important cornerstone in the continuum of modern cancer care. Although, in many aspects, critical care for patients with cancer does not differ from intensive care for other seriously ill patients, there are several challenging issues that are unique to this patient population and require special knowledge and skills. The optimal management of critically ill patients with cancer necessitates expertise in oncology, critical care, and palliative medicine. Cancer specialists therefore have to be familiar with key principles of intensive care for critically ill patients with cancer. This review provides an overview of the state‐of‐the‐art in the individualized management of critically ill patients with cancer. CA Cancer J Clin 2016;66:496–517. © 2016 American Cancer Society .
- 27 June 2016
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 66 (6) , 496-517
Critical care of patients with cancer
Answer questions and earn CME/CNE The increasing prevalence of patients living with cancer in conjunction with the rapid progress in cancer therapy will lead to a growing number of patients with cancer who will require intensive care treatment. Fortunately, the development of more effective oncologic therapies, advances in critical care, and improvements in patient selection have led to an increased survival of critically ill patients with cancer. As a consequence, critical care has become an important cornerstone in the continuum of modern cancer care. Although, in many aspects, critical care for patients with cancer does not differ from intensive care for other seriously ill patients, there are several challenging issues that are unique to this patient population and require special knowledge and skills. The optimal management of critically ill patients with cancer necessitates expertise in oncology, critical care, and palliative medicine. Cancer specialists therefore have to be familiar with key principles of intensive care for critically ill patients with cancer. This review provides an overview of the state‐of‐the‐art in the individualized management of critically ill patients with cancer. CA Cancer J Clin 2016;66:496–517. © 2016 American Cancer Society .
- 16 July 2015
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 140 (14) , e136-e141
Personalbedarf einer Intensivstation unter Berücksichtigung geltender Hygienerichtlinien
Die Anzahl der behandelten Patienten auf Intensivstationen nimmt immer mehr zu. Lebensalter, Komorbiditäten und komplexe Behandlungsmethoden führen zu einem Anstieg von Patienten, die mit Antibiotika-resistenten Erregern entweder kolonisiert oder infiziert sind. Für die Vermeidung nosokomialer Infektionen spielen Hygienerichtlinien eine wichtige Rolle. In dieser Arbeit untersuchen wir den Zeitaufwand von Pflegekräften bei der Versorgung von Intensivpatienten an fünf Modellpatienten. Die Ergebnisse zeigen, dass der derzeitige Personalbedarfsplan unter den gegebenen Hygienerichtlinien nicht ausreicht. Danach ist eine 1:1-Betreuung unbedingt notwendig. In einer nationalen Umfrage unter Universitätskliniken wurde ein Verhältnis von Pflegekraft zu Patienten von 1:2,47 ermittelt. Pflegekräften auf Intensivstationen ist die Hygieneproblematik bekannt und wichtig – mit hohem persönlichen Einsatz versuchen sie, diese umzusetzen. The patient burden in intensive care units (ICU) has continually increased worldwide over the past decades. Age, co-morbidities and an increasing complexity of conditions and treatments increase the number of patients who are either colonized or infected with antibiotic-resistant pathogens. To prevent nosocomial infections, hygiene guidelines play an important role. In this paper, we investigate the time needed for nursing of five hypothetical critically ill patients in the intensive care unit. The results show that current staffing is not sufficient under the given hygiene guidelines and that a nurse to patient ratio of one will be necessary to meet the requirements. In a national survey of university hospitals, however, we found that the current nurse to patient ratio is 1: 2.47 in German intensive care units. The apparent staffing shortage is compensated by an extraordinary personal commitment of nurses caring for patients in the ICU.
- 16 July 2015
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 140 (14) , e136-e141
Personalbedarf einer Intensivstation unter Berücksichtigung geltender Hygienerichtlinien
Die Anzahl der behandelten Patienten auf Intensivstationen nimmt immer mehr zu. Lebensalter, Komorbiditäten und komplexe Behandlungsmethoden führen zu einem Anstieg von Patienten, die mit Antibiotika-resistenten Erregern entweder kolonisiert oder infiziert sind. Für die Vermeidung nosokomialer Infektionen spielen Hygienerichtlinien eine wichtige Rolle. In dieser Arbeit untersuchen wir den Zeitaufwand von Pflegekräften bei der Versorgung von Intensivpatienten an fünf Modellpatienten. Die Ergebnisse zeigen, dass der derzeitige Personalbedarfsplan unter den gegebenen Hygienerichtlinien nicht ausreicht. Danach ist eine 1:1-Betreuung unbedingt notwendig. In einer nationalen Umfrage unter Universitätskliniken wurde ein Verhältnis von Pflegekraft zu Patienten von 1:2,47 ermittelt. Pflegekräften auf Intensivstationen ist die Hygieneproblematik bekannt und wichtig – mit hohem persönlichen Einsatz versuchen sie, diese umzusetzen. The patient burden in intensive care units (ICU) has continually increased worldwide over the past decades. Age, co-morbidities and an increasing complexity of conditions and treatments increase the number of patients who are either colonized or infected with antibiotic-resistant pathogens. To prevent nosocomial infections, hygiene guidelines play an important role. In this paper, we investigate the time needed for nursing of five hypothetical critically ill patients in the intensive care unit. The results show that current staffing is not sufficient under the given hygiene guidelines and that a nurse to patient ratio of one will be necessary to meet the requirements. In a national survey of university hospitals, however, we found that the current nurse to patient ratio is 1: 2.47 in German intensive care units. The apparent staffing shortage is compensated by an extraordinary personal commitment of nurses caring for patients in the ICU.
- 2 December 2014
- Published by Springer Nature in best practice onkologie
- Vol. 9 (6) , 22-28
Intensivmedizinisches Management hämatologischer und onkologischer Patienten
- 2 December 2014
- Published by Springer Nature in best practice onkologie
- Vol. 9 (6) , 22-28
Intensivmedizinisches Management hämatologischer und onkologischer Patienten
- Open Access
- 1 November 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, vi3
Microtubule-Depolymerizing Agents Used in Antibody-Drug-Conjugates Induce Antitumor Activity by Stimulation of Dendritic Cells
Antibody drug conjugates (ADCs) are emerging as powerful treatment strategies with outstanding target specificity and high therapeutic activity in cancer patients. While >30 ADCs are currently being investigated in clinical trials, brentuximabvedotin and T-DM1 represent clinically approved ADCs in cancer patients. We hypothesized that their sustained clinical responses could be related to the stimulation of an antitumor immune response. Indeed, the two microtubule-destabilizing agents Dolastatin 10 and Ansamitocin P3, from which the cytotoxic components of brentuximabvedotin and T-DM1 are derived, may serve as prototypes for a class of agents that induce tumor cell death and convert tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs). The two drugs induced phenotypic and functional maturation of murine splenic as well as human monocyte-derived DCs. In contrast, microtubule-stabilizing agents such as taxanes did not display this feature. In tumor models, both Dolastatin 10 and Ansamitocin P3 efficiently promoted antigen uptake and migration of tumor-resident DCs to tumor-draining lymph nodes, thereby potentiating tumor-specific T cell responses. Underlining the requirement of an intact host immune system for the full therapeutic benefit of these two compounds, their antitumor effect was far less pronounced in mice lacking adaptive immunity or dendritic cells. Combinations with immune checkpoint inhibition (anti-CTLA-4/-PD-1) did further augment antitumor immunity and tumor rejection, which was reflected by reduced Treg numbers and elevated effector function of tumor resident T cells. Ultimately, we were able to demonstrate peripheral immune cell activation and brisk T cell infiltration into tumors in patients previously treated with BrentuximabVedotin. Experiments are currently ongoing to investigate the immunological mode of action of T-DM1 using orthotopic breast cancer models and patients undergoing treatment. Our data reveal a novel mode of action for microtubule-depolymerizing agents and provide a strong rationale for clinical treatment regimens combining these with immune-based therapies. Disclosure: All authors have declared no conflicts of interest.
- 1 November 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, vi3
Open AccessMicrotubule-Depolymerizing Agents Used in Antibody-Drug-Conjugates Induce Antitumor Activity by Stimulation of Dendritic Cells
Antibody drug conjugates (ADCs) are emerging as powerful treatment strategies with outstanding target specificity and high therapeutic activity in cancer patients. While >30 ADCs are currently being investigated in clinical trials, brentuximabvedotin and T-DM1 represent clinically approved ADCs in cancer patients. We hypothesized that their sustained clinical responses could be related to the stimulation of an antitumor immune response. Indeed, the two microtubule-destabilizing agents Dolastatin 10 and Ansamitocin P3, from which the cytotoxic components of brentuximabvedotin and T-DM1 are derived, may serve as prototypes for a class of agents that induce tumor cell death and convert tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs). The two drugs induced phenotypic and functional maturation of murine splenic as well as human monocyte-derived DCs. In contrast, microtubule-stabilizing agents such as taxanes did not display this feature. In tumor models, both Dolastatin 10 and Ansamitocin P3 efficiently promoted antigen uptake and migration of tumor-resident DCs to tumor-draining lymph nodes, thereby potentiating tumor-specific T cell responses. Underlining the requirement of an intact host immune system for the full therapeutic benefit of these two compounds, their antitumor effect was far less pronounced in mice lacking adaptive immunity or dendritic cells. Combinations with immune checkpoint inhibition (anti-CTLA-4/-PD-1) did further augment antitumor immunity and tumor rejection, which was reflected by reduced Treg numbers and elevated effector function of tumor resident T cells. Ultimately, we were able to demonstrate peripheral immune cell activation and brisk T cell infiltration into tumors in patients previously treated with BrentuximabVedotin. Experiments are currently ongoing to investigate the immunological mode of action of T-DM1 using orthotopic breast cancer models and patients undergoing treatment. Our data reveal a novel mode of action for microtubule-depolymerizing agents and provide a strong rationale for clinical treatment regimens combining these with immune-based therapies. Disclosure: All authors have declared no conflicts of interest.
- 18 October 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (11) , 1306-1312
Transplantation hämatopoetischer Stammzellen
The number of hematopoietic stem cell transplantations is continuously increasing. On the one hand reduced intensity conditioning and improved supportive therapies allow for transplantations in patients with significant comorbidities and up to their eighth decade of life. Due to this development the number of complex and critically ill patients in need of intensive care is constantly growing. Recent developments in general critical care such as sepsis bundles and non-invasive ventilation contribute to a better outcome of these patients. However, treatment algorithms that identify patients potentially benefitting from intensive care but also reduce overtreatment of moribund patients represent a central multidisciplinary challenge not only for the treating transplant physician and intensivist.
- 18 October 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (11) , 1306-1312
Transplantation hämatopoetischer Stammzellen
The number of hematopoietic stem cell transplantations is continuously increasing. On the one hand reduced intensity conditioning and improved supportive therapies allow for transplantations in patients with significant comorbidities and up to their eighth decade of life. Due to this development the number of complex and critically ill patients in need of intensive care is constantly growing. Recent developments in general critical care such as sepsis bundles and non-invasive ventilation contribute to a better outcome of these patients. However, treatment algorithms that identify patients potentially benefitting from intensive care but also reduce overtreatment of moribund patients represent a central multidisciplinary challenge not only for the treating transplant physician and intensivist.
- 28 March 2014
- Published by Springer Nature in Wiener klinisches Magazin
- Vol. 17 (2) , 18-22
Intensivmedizinisches Management hämatologischer und onkologischer Patienten
- 28 March 2014
- Published by Springer Nature in Wiener klinisches Magazin
- Vol. 17 (2) , 18-22
Intensivmedizinisches Management hämatologischer und onkologischer Patienten
- Open Access
- 25 August 2013
- Published by Springer Nature in Die Innere Medizin
- Vol. 54 (9) , 1041-1042
Onkologische und hämatologische Notfälle
- 25 August 2013
- Published by Springer Nature in Die Innere Medizin
- Vol. 54 (9) , 1041-1042
Open AccessOnkologische und hämatologische Notfälle
- 22 August 2013
- Published by Springer Nature in Die Innere Medizin
- Vol. 54 (9) , 1080-1086
Intensivmedizinisches Management hämatologischer und onkologischer Patienten
- 22 August 2013
- Published by Springer Nature in Die Innere Medizin
- Vol. 54 (9) , 1080-1086
Intensivmedizinisches Management hämatologischer und onkologischer Patienten